06/12/2018 23:00:00

New Clinical Data Further Validate SAVI SCOUT® Radar Localization System for Simpler, Positive Axillary Lymph Node Localization

Poster Presentation at San Antonio Breast Cancer Symposium shows 100% successful wire-

free localization with no migration throughout neoadjuvant chemotherapy treatment

SAN ANTONIO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Data presented this week on wire-free radar breast localization demonstrated it may be a practical approach for positive axillary lymph node localization prior to neoadjuvant chemotherapy treatment (NAT) response. 

The poster presented preliminary data from a subset analysis of an investigator-initiated, prospective study, documenting that among 24 node-positive patients, 100 percent had successful wire-free localization (WFL) placement with 0.0 mm migration throughout NAT on standard-of-care preoperative surveillance imaging (mammogram, ultrasound, MRI and PET/CT).  Both the target lymph node and WFL were visualized on MRI and PET/CT imaging. WFL successfully supplemented sentinel lymph node surgery in the surgical cases completed to date (14/14).

“This subset analysis suggests that placement of a wire-free radar localization implant prior to NAT can be performed long-term prior to neoadjuvant treatment response when the lesion is clearly visualized on imaging—with no significant adverse effects or migration,” stated Mary K. Hayes, MD. “Since successful neoadjuvant therapy can result in a complete or partial response, a simpler pre-neoadjuvant, imaged-guided wire-free radar localization may replace the more difficult and less reliable wire localization currently done after NAT response.” Having served as the Medical Director of Women’s Imaging at Memorial Healthcare System in Hollywood, Fla. for nearly 20 years, Dr. Hayes has since expanded clinical and research work as a principal investigator at Envision Physician Services Scientific Intelligence teams.

“This may be a more precise method of identifying the biopsy proven positive lymph node following NAT and assuring its removal at the time of surgery,” commented Erica Bloomquist, MD, breast surgical oncologist and study investigator. “Older methods of localizing this lymph node could result in leaving it behind in the axilla at the time of axillary evaluation and consequently a higher false negative rate for targeted axillary dissection.”

Joining her colleagues as study investigator, Heather Wright, MD, Director of Breast Surgical Oncology noted, “If more studies continue to support these findings, we could see a paradigm shift in the standard of care for patients with known axillary disease and planned NAT.”

“These promising results underscore why radar is the technology of choice for tumor localization both in the breast and now in lymph nodes,” said Mike Numamoto, Vice President of Marketing, Cianna Medical. “SCOUT® is uniquely suited for placement prior to neoadjuvant chemotherapy treatment, as shown in this study.” It is important to note that SCOUT does not interfere with MRI imaging. This SCOUT and lesion visibility is important for standard-of-care pre-surgical planning. 

SCOUT, a tool for localizing and directing the removal of non-palpable breast lesions, has undergone rapid adoption and is now FDA-cleared for long term use in the breast and soft tissues. SCOUT is now in use at more than 400 hospitals across the United States. More than 58,000 women have had a wire-free localization experience with SCOUT.

About SCOUT®

SCOUT is uniquely suited for marking tumors and biopsy sites prior to neoadjuvant therapy. The SCOUT reflector has a clinically insignificant MRI artifact, it does not interfere with MRI studies, so there is no restriction on the imaging modalities that can be used effectively throughout treatment. With seven peer-reviewed publications and over 20 clinical abstracts, SCOUT has been proven to be easy to use and provides accurate detection and precise localization. SCOUT also has been shown to improve radiology work flow and significantly reduce OR delays. SCOUT has received significant recognition from medical societies and industry associations including the ASBS Scientific Impact Award, the Gold Award for Medical Design Excellence Award and the Premier Innovation Award. Please visit www.ciannamedical.com.

About Merit Medical

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling in excess of 300 individuals. Merit employs approximately 5,600 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore.

Media Contact:                                                                                                       

Erich Sandoval

LAZAR PARTNERS for Cianna Medical

esandoval@lazarpartners.com

(917) 497-2867

Cianna Logo.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Feb
VWS
  Jeg har nu haft lidt tid til at læse det seneste årsregnskab fra Vestas. Jeg har forsøgt at opsumm..
62
21 Feb
VELO
Især 2 ting har fanget min opmærksomhed i de seneste døgn. 1) Astellas er udtrådt af AST )American S..
22
21 Feb
CHEMM
Vi sidder her under træet og bliver helt skizofrene. Hvad skete der lige her. Tælleren tog et hop op..
18
19 Feb
FING-B
Så lukkede FPC over den gamle modstand i dag i 19,55 modstanden var 19,47 og næste stop er nu 21,786..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
18 Feb
VWS
VESTAS LEADS BREAK-AWAY GROUP OF ONSHORE TURBINE MAKERS (fra 16% til 22% af det totale marked for la..
17
18 Feb
PNDORA
Det er netop kommet frem, at tyske BAFIN, svarende til Finanstilsynet i Dk., har forbudt short posit..
17
21 Feb
GEN
Igen i dag ses de Anonyme (ANON) dvs. hovedsageligt shorterne - hen over dagen næsten desperat søger..
16
19 Feb
VELO
Til dem af jer der ikke er med i FB gruppen: Canada havde, sammen med US, lukket i går. Teorien er, ..
16
18 Feb
CHEMM
Puha, ja hvad venter vi nu på,…… vi trofaste og frelste Chemo aktionærer, Noten, den romantiske og ..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
2
Bragar Eagel & Squire, P.C. is Investigating Domino’s Pizza, Inc. (DPZ) on Behalf of Stockholders and Encourages DPZ Investors to Contact the Firm
3
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
4
Odyssey Moon Extends Its Heartfelt Congratulations to SpaceIL for the Successful Launch of the First Non-Governmental Spacecraft to the Moon
5
Bragar Eagel & Squire, P.C. is Investigating Vanda Pharmaceuticals Inc. (VNDA) on Behalf of Stockholders and Encourages VNDA Investors to Contact the Firm

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 13:21:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB1 - 2019-02-22 14:21:02 - 2019-02-22 13:21:02 - 1000 - Website: OKAY